Recent development in carbohydrate-based cancer vaccines
- 31 December 2009
- journal article
- review article
- Published by Elsevier BV in Current Opinion in Chemical Biology
- Vol. 13 (5-6), 608-617
- https://doi.org/10.1016/j.cbpa.2009.08.010
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Induction of a Melanoma‐Specific Antibody Response by a Monovalent, but not a Divalent, Synthetic GM2 NeoglycopeptideChemMedChem, 2009
- Efficient glycoengineering of GM3 on melanoma cell and monoclonal antibody-mediated selective killing of the glycoengineered cancer cellBioorganic & Medicinal Chemistry, 2007
- Efficient Metabolic Engineering of GM3 on Tumor Cells by N-Phenylacetyl-d-mannosamineBiochemistry, 2006
- Synthesis and Immunological Properties of N-Modified GM3 Antigens as Therapeutic Cancer VaccinesJournal of Medicinal Chemistry, 2005
- Vaccination with Theratope® (STn-KLH) as treatment for breast cancerExpert Review of Vaccines, 2004
- Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccinesVaccine, 2001
- Anti-Tumor Immunity Provided by a Synthetic Multiple Antigenic Glycopeptide Displaying a Tri-Tn GlycotopeThe Journal of Immunology, 2001
- Tumor-Associated Carbohydrate Antigens Defining Tumor Malignancy: Basis for Development of Anti-Cancer VaccinesAdvances in Experimental Medicine and Biology, 2001
- Immune surveillance against a solid tumor fails because of immunological ignoranceProceedings of the National Academy of Sciences of the United States of America, 1999
- Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen.1995